Published online Sep 25, 2024. doi: 10.5501/wjv.v13.i3.91107
Revised: June 22, 2024
Accepted: July 23, 2024
Published online: September 25, 2024
Processing time: 233 Days and 12.8 Hours
Viral and bacterial infections may be complicated by rhabdomyolysis, which has a spectrum of clinical presentations ranging from asymptomatic laboratory abnor
To compare rhabdomyolysis-related AKI with other AKIs during COVID-19.
A total of 115 patients with COVID-19 who had AKI were evaluated retrospec
For patients with rhabdomyolysis, creatinine reached 2.47 ± 1.17 mg/dL during follow-up in hospital. Of these patients, 13.3% had AKI upon hospital admission, and 86.4% developed AKI during hospital follow-up. Their peak C-reactive protein reached as high as 253.2 ± 80.6 mg/L and was higher than in patients with AKI due to other reasons (P < 0.01). Peak ferritin and procalcitonin levels were also higher for patients with rhabdomyolysis (P = 0.02 and P = 0.002, respective
Rhabdomyolysis was present in 13.0% of the patients who had AKI during COVID-19 infection. Rhabdomyolysis-related AKI is more proinflammatory and has a more mortal clinical course.
Core Tip: This study investigated rhabdomyolysis-related acute kidney injury (AKI) in patients with coronavirus disease 2019 (COVID-19) and compared it with COVID-19-related AKI due to other causes. Patients with rhabdomyolysis had more inflammation with higher levels of C-reactive protein, procalcitonin, and ferritin. The prognosis of rhabdomyolysis-related AKI was worse than for other forms of COVID-19-related AKI. Patients with inflammatory viral infections such as COVID-19 should be closely followed up for life-threatening conditions such as rhabdomyolysis.
- Citation: Murt A, Altiparmak MR. Rhabdomyolysis-related acute kidney injury in patients with COVID-19. World J Virol 2024; 13(3): 91107
- URL: https://www.wjgnet.com/2220-3249/full/v13/i3/91107.htm
- DOI: https://dx.doi.org/10.5501/wjv.v13.i3.91107
Rhabdomyolysis is characterized by extensive muscular injury and the release of intracellular components into the systemic circulation. The severity of rhabdomyolysis may range from asymptomatic enzyme elevations to electrolyte abnormalities and even life-threatening conditions. Symptoms of rhabdomyolysis include myalgia, muscle weakness, and red/brown urine.
Trauma, strenuous exercise, hyperthermia, and toxin exposures are the main etiologies of rhabdomyolysis, but it can also be caused by infections and sepsis[1]. Among infectious agents, viruses constitute a considerable part. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can also cause rhabdomyolysis. There are different theoretical mecha
Independent of rhabdomyolysis, acute kidney injury (AKI) may be seen in the course of COVID-19, and it is related to poor prognosis[4]. Rhabdomyolysis may further complicate the clinical course as an additional risk factor for AKI. Rhabdomyolysis was found as the background etiology for 7% of patients who had AKI in the course of COVID-19[5].
This study aimed to compare rhabdomyolysis-related AKI with other types of AKI in COVID-19. Such analysis may provide insights for physicians to manage different viral infections that may cause AKI and rhabdomyolysis.
The study was conducted at Cerrahpasa Medical Faculty, Istanbul, Türkiye, which serves as a tertiary healthcare center. During the pandemic, the university hospital was designated as a pandemic control hospital. The first wave of patients with COVID-19 from the pandemic was between 15 March to 15 June 2020. To study the sole relation between COVID-19 and AKI, those who had prior chronic kidney disease (CKD) were excluded from the study. Patients who had rhabdomyolysis-related in-hospital AKI were involved in the study.
COVID-19 was diagnosed using real-time polymerase chain reaction test from combined nasal and oral swabs.
AKI was diagnosed according to the Kidney Diseases Improving Global Outcomes (KDIGO) criteria: An absolute increase in creatinine levels by 0.3 mg/dL in the last 48 h or a 50% increase in creatinine levels in the last 7 d. AKI was also categorized according to the KDIGO criteria: A 1.5–1.9 times increase was classed as stage I, a 2.0–2.9 times increase was considered as stage II, and > 3.0 times or increase to > 4.0 mg/dL was accepted as stage III. Baseline creatinine was defined as the lowest creatinine level in the last 6 mo, excluding the last 7 d. This was detected via a nationwide electronic health record system. Rhabdomyolysis was diagnosed in patients who had creatine kinase (CK) levels that were higher than five times the upper normal level with concomitant increases in transaminases and lactate dehydrogenase (LDH).
Patients who were diagnosed as having COVID-19 and had AKI were admitted to the designated COVID-19 wards in the hospital. They received all supportive care according to the guidelines released and regularly updated by the Turkish Ministry of Health COVID-19 Scientific Steering Committee. Hemogram, C-reactive protein (CRP), procalcitonin, pro-brain natriuretic peptide (proBNP), urea, creatinine, electrolyte levels, and oxygen saturation were checked daily. When needed, patients were admitted to intensive care units, receiving all necessary medical care. The endpoint for patient follow-up was either hospital discharge or death.
The normality of the distribution of continuous data was assessed using the Kolmogorov–Smirnov test. Continuous data with normal distribution are presented as mean ± SD and those with non-normal distribution are presented as median and interquartile range. Between-group analysis of continuous data was performed using the independent samples Students’ t test or Mann–Whitney U test depending on the normality of the distribution. Categorical variables are presented as percentages and compared using the χ2 test. IBM SPSS version 22.0 was used for statistical analysis. A two-sided P < 0.05 was accepted as statistically significant.
Among 115 patients who had AKI in this first wave of the pandemic, 15 had concomitant rhabdomyolysis. Two patients had AKI on the day of hospital admission and the remaining 13 developed new-onset AKI during hospital admission. The mean day of AKI was 7.4 days ± 3.1 d for these 13 patients.
In the comparison of patients with rhabdomyolysis-related AKI and other patients with AKI, age, baseline creatinine levels, and sex distribution were similar. In addition, the rates of both hypertension and diabetes between these two groups were also similar (Table 1).
Rhabdomyolysis (n = 15) | Other AKI (n = 100) | P value | |
Age, yr | 61.00 ± 19.10 | 62.60 ± 13.50 | 0.70 |
Baseline creatinine (mg/dL) | 0.86 ± 0.13 | 0.92 ± 0.15 | 0.25 |
Gender (%, male) | 73.3 | 75.0 | 0.86 |
Hypertension | 6 (40.0) | 28 (28.0) | 0.34 |
Diabetes | 5 (33.3) | 21 (21.0) | 0.30 |
The complete blood count and hemoglobin levels of patients were comparable (Table 2). The mean arterial pressure of both groups was also similar. Peak creatinine levels of patients with rhabdomyolysis were higher. In addition, patients with AKI and rhabdomyolysis had lower lymphocyte counts and higher CRP levels. Procalcitonin and peak procalcitonin levels were also higher for patients with both AKI and rhabdomyolysis. Although on-admission ferritin levels were similar for both groups, patients with rhabdomyolysis had higher peak ferritin levels indicating a greater inflammatory response.
Rhabdomyolysis (n = 15) | Other AKI (n = 100) | P value | |
Peak creatinine (mg/dL) | 2.47 ± 1.17 | 1.62 ± 0.58 | 0.000 |
Mean arterial pressure (mmHg) | 89.75 ± 8.63 | 88.63 ± 14.38 | 0.790 |
Hemoglobin (g/dL) | 12.59 ± 1.83 | 12.26 ± 1.83 | 0.560 |
Lymphocytes (μL) | 941.60 ± 311.70 | 1362.30 ± 676.10 | 0.010 |
Nadir lymphocytes (μL) | 533.30 ± 280.60 | 957.90 ± 618.80 | 0.020 |
CRP (mg/L) | 111.12 ± 69.91 | 77.45 ± 78.41 | 0.140 |
Peak CRP (mg/dL) | 253.24 ± 80.67 | 156.95 ± 111.20 | 0.000 |
Procalcitonin (ng/mL) | 0.28 [0.12-0.75] | 0.10 [0.06-0.28] | 0.018 |
Peak procalcitonin (ng/mL) | 1.61 [0.40-10.60] | 0.16 [0.08-1.03] | 0.002 |
Creatine kinase (U/L) | 260.00 [123.50-1057.20] | 94.50 [58.0-203.70] | 0.005 |
Peak CK (U/L) | 1929.30 ± 1282.20 | 238.10 ± 237.0 | 0.000 |
Median: 1514.0 | Median: 126.50 | ||
Ferritin (ng/mL) | 669.0 [195.90-1403.50] | 366.00 [192.50-884.0] | 0.360 |
Peak ferritin (ng/mL) | 1320.10 ± 590.0 | 967.10 ± 1038.70 | 0.020 |
Median: 1267.50 | Median: 657.0 | ||
LDH (U/L) | 469.40 ± 162.70 | 408.00 ± 350.0 | 0.550 |
Peak LDH (U/L) | 964.90 ± 409.60 | 654.70 ± 61.80 | 0.030 |
Albumin (g/dL) | 3.15 ± 0.49 | 3.44 ± 0.49 | 0.057 |
D-dimer (μg FEU/mL) | 1.62 ± 1.34 | 1.93 ± 3.17 | 0.730 |
Peak d-dimer (μg FEU/mL) | 23.40 ± 22.50 | 7.90 ± 11.07 | 0.030 |
Uric acid (mg/dL) | 4.85 ± 2.18 | 5.81 ± 2.18 | 0.160 |
HCO3- (mmol/L) | 21.51 ± 8.71 | 24.98 ± 4.53 | 0.220 |
Peak creatinine levels in the follow-up were significantly higher for patients with rhabdomyolysis. In other words, AKI was more severe for patients with rhabdomyolysis, with 80% of them having stage II or III AKI. In contrast, AKI without rhabdomyolysis was milder (84.4% of these patients had stage I AKI) (Table 3). Patients with AKI and rhabdomyolysis had significantly higher proBNP levels, higher intensive care unit admissions, and higher mortality than patients with AKI due to other causes. Mortality of rhabdomyolysis-related AKI was 73.3%, whereas it was 18.0% for other patients with AKI. However, the rate of hyperkalemia was not different for both groups.
Rhabdomyolysis (n = 15) | Other AKI (n = 100) | P value | |
AKI stage I, II, III (%) | 20.0; 33.3; 46.7 | 85.0; 10.0; 5.0 | 0.000 |
ICU admission | 12 (80.0) | 27 (27.0) | 0.002 |
Mortality | 11 (73.3) | 18 (18.0) | 0.001 |
Pro-BNP (pg/mL) | 7460 [1451.0-34624.0] | 583 [99.7-4203.0] | 0.003 |
Hyperkalemia | 8 (53.3) | 39 (39.0) | 0.270 |
While AKI may develop due to a variety of reasons during COVID-19[6], rhabdomyolysis is one of the specific risk factors. In patients with rhabdomyolysis, non-protein heme pigment is mainly responsible for the occurrence of AKI[7]. Although some drugs may cause rhabdomyolysis, it was not attributed to any medication in our patient cohort. In the pathophysiology of rhabdomyolysis-related AKI, vasoconstriction, tubular injury, and/or tubular obstruction can be responsible factors. Avoiding volume depletion is the main strategy to prevent AKI in rhabdomyolysis. Also, prescribing relevant fluid treatments decreases intratubular cast formation. However, fluid administration during COVID-19 was advised to be restricted, with a fear that it may result in lung edema[8].
Previously, our group and other researchers have shown that, when complicated with AKI, COVID-19 has a worse prognosis[9,10]. However, the prognosis of different etiologies for AKI was not compared in the vast majority of studies. This is mainly because of the difficulty in finding the exact etiology of AKI in the course of COVID-19. Because of the respiratory nature of the disease, acute tubular necrosis due to hypoxemia has been accepted as the main factor of AKI in COVID-19. Hypercoagulopathy and the inflammatory nature of the disease may result in intrarenal injuries including microangiopathies. The exact etiology is seldom defined because performing a kidney biopsy is not possible for most patients with unstable clinical conditions. However, rhabdomyolysis can generally be diagnosed with clinical signs, symptoms, and laboratory findings. We identified 15 patients with rhabdomyolysis among our patients with COVID-19-related AKI.
AKI was more severe in patients with rhabdomyolysis. This was apparent with higher mean creatinine levels and more patients having stage II and III AKI (33.3% and 46.7%, respectively). In contrast, the majority of AKIs in the other group were stage I (84.4%). Rhabdomyolysis-related AKI generally occurs concurrently with hyperkalemia, which may be another reason for the higher mortality. We also found that mortality was significantly higher for patients with rhabdomyolysis; however, the rate of hyperkalemia was similar for both groups. Thus, the higher mortality of rhabdomyolysis could not be attributed to hyperkalemia. Accordingly, there must be other factors that increase mortality in patients with COVID-19 with rhabdomyolysis.
Similar to prior reports, rhabdomyolysis in our patients with AKI either started late or worsened during follow-up[11]. Thus, CK, urea, and creatinine levels, as well as electrolytes should be closely monitored in viral infections with inflammatory characteristics. We performed daily laboratory checks because patients could rapidly deteriorate. We found much higher peak ferritin and D-dimer levels in patients with both AKI and rhabdomyolysis. This may point to increased coagulation and inflammation in cases of COVID-19 with rhabdomyolysis. Higher hypercoagulopathy and systemic inflammation may be drivers of additional muscular injury.
We found higher proBNP levels in patients with AKI with rhabdomyolysis. N-terminal pro-BNP may be elevated in cardiac stress. It may also be elevated due to increased pulmonary tension in hypoxemia. Higher proBNP is indepen
Procalcitonin levels were also higher in patients with both AKI and rhabdomyolysis. Previous reports have underlined procalcitonin as a prognostic biomarker for severe COVID-19[14]. Procalcitonin is released in the inflammatory state as a response to proinflammatory cytokines. Higher peak CRP, LDH, and ferritin levels in rhabdomyolysis may show a worse inflammatory state in patients with rhabdomyolysis compared with other AKIs. Our findings show the utility of procalcitonin in the follow-up of patients with severe COVID-19.
This study had some limitations. First, the sample size was small. This is because of the exclusion of patients who already had CKD and applying strict clinical criteria to diagnose rhabdomyolysis. Nevertheless, such an approach ensured the exact accuracy of diagnosis. Secondly, kidney biopsies could not be performed due to the disease severity and scarcity of such resources during the first wave of the pandemic. Lastly, this study focused on the first wave of the pandemic.
Rhabdomyolysis may complicate the clinical course of COVID-19 and it is one of the major etiologies for AKI. When compared with AKI due to other causes, patients with rhabdomyolysis had higher inflammatory and hypercoagulopathy markers. The prognosis of rhabdomyolysis-related AKI is worse than for other AKIs.
1. | Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med. 2007;18:90-100. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 177] [Cited by in F6Publishing: 179] [Article Influence: 10.5] [Reference Citation Analysis (0)] |
2. | Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007;2:210-218. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 245] [Cited by in F6Publishing: 235] [Article Influence: 13.8] [Reference Citation Analysis (0)] |
3. | Haroun MW, Dieiev V, Kang J, Barbi M, Marashi Nia SF, Gabr M, Eman G, Kajita G, Swedish K. Rhabdomyolysis in COVID-19 Patients: A Retrospective Observational Study. Cureus. 2021;13:e12552. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
4. | Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, Rimmelé T, Zarbock A, Bell S, Bihorac A, Cantaluppi V, Hoste E, Husain-Syed F, Germain MJ, Goldstein SL, Gupta S, Joannidis M, Kashani K, Koyner JL, Legrand M, Lumlertgul N, Mohan S, Pannu N, Peng Z, Perez-Fernandez XL, Pickkers P, Prowle J, Reis T, Srisawat N, Tolwani A, Vijayan A, Villa G, Yang L, Ronco C, Kellum JA. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16:747-764. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 455] [Cited by in F6Publishing: 387] [Article Influence: 96.8] [Reference Citation Analysis (0)] |
5. | Mohamed MMB, Lukitsch I, Torres-Ortiz AE, Walker JB, Varghese V, Hernandez-Arroyo CF, Alqudsi M, LeDoux JR, Velez JCQ. Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans. Kidney360. 2020;1:614-622. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 126] [Cited by in F6Publishing: 130] [Article Influence: 32.5] [Reference Citation Analysis (0)] |
6. | Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, Jhaveri KD; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98:209-218. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 939] [Cited by in F6Publishing: 963] [Article Influence: 240.8] [Reference Citation Analysis (0)] |
7. | Zager RA. Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Lab Invest. 1989;60:619-629. [PubMed] [Cited in This Article: ] |
8. | Matsumura Y, Sugiyama T, Kondo N, Miyahara M, Hanaoka N, Nagashima H, Kasahara Y, Fujiyoshi N, Inada A, Inaba S. Fluid restriction management in the treatment of COVID-19: a single-center observational study. Sci Rep. 2022;12:17339. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
9. | Murt A, Dinçer MT, Karaca C, Trabulus S, Karaali R, Balkan II, Seyahi N, Altıparmak MR. Acute Kidney Injury in Cases of COVID-19 Without ExistingKidney Disease: Does It Differ at Various Stages of the Disease? Cerrahpaşa Med J. 2022;1-9. [DOI] [Cited in This Article: ] |
10. | Robbins-Juarez SY, Qian L, King KL, Stevens JS, Husain SA, Radhakrishnan J, Mohan S. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney Int Rep. 2020;5:1149-1160. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 159] [Cited by in F6Publishing: 142] [Article Influence: 35.5] [Reference Citation Analysis (0)] |
11. | Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020;26:1618-1620. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 218] [Cited by in F6Publishing: 236] [Article Influence: 59.0] [Reference Citation Analysis (0)] |
12. | Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, Italia L, Zaccone G, Tedino C, Fabbricatore D, Curnis A, Faggiano P, Gorga E, Lombardi CM, Milesi G, Vizzardi E, Volpini M, Nodari S, Specchia C, Maroldi R, Bezzi M, Metra M. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J. 2020;41:1821-1829. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 332] [Cited by in F6Publishing: 361] [Article Influence: 90.3] [Reference Citation Analysis (0)] |
13. | Rodríguez E, Soler MJ, Rap O, Barrios C, Orfila MA, Pascual J. Risk factors for acute kidney injury in severe rhabdomyolysis. PLoS One. 2013;8:e82992. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 53] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
14. | Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-191. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 322] [Cited by in F6Publishing: 367] [Article Influence: 91.8] [Reference Citation Analysis (0)] |